Opinion

Video

Approaching Management of Fibromyalgia and Unmet Needs in Treatment

Dr Daniel J. Clauw provides an overview of pharmacologic and nonpharmacologic therapeutic approaches for the management of fibromyalgia and comments on challenges and unmet needs for patients.

This is a video synopsis of a discussion involving Daniel J. Clauw, MD, a professor of anesthesiology, medicine/rheumatology, and psychiatry at the University of Michigan. Dr. Clauw discusses the treatment approaches for fibromyalgia, emphasizing the increasing understanding that non-drug therapies are likely preferable in conjunction with pharmaceutical interventions.

He identifies three general categories of drugs that may be helpful for fibromyalgia: tricyclic drugs, serotonin-norepinephrine reuptake inhibitors (SNRIs), and gabapentinoids. Dr. Clauw introduces the concept of drugs as a "chemical nudge," helping individuals with fibromyalgia manage symptoms such as fatigue, pain, and sleep disturbances, enabling them to engage in non-drug therapies effectively. Non-pharmacologic strategies, including improving sleep, increasing activity levels, and stress reduction, play a significant role in managing fibromyalgia and nociplastic pain.

Dr. Clauw acknowledges the challenges in fibromyalgia care, including delayed identification and treatment initiation. He stresses the importance of early identification and aggressive treatment to prevent the accumulation of psychosocial factors that exacerbate pain and complicate treatment. Despite progress, there is still a need to overcome physician misunderstandings and reduce the stigma associated with fibromyalgia, advocating for a comprehensive approach to improve the lives of individuals with fibromyalgia-like pain.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.